Literature DB >> 33526329

Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials.

Lorenzo Marconi1, Maxine Sun2, Christian Beisland3, Tobias Klatte4, Boerje Ljungberg5, Grant D Stewart6, Saeed Dabestani7, Toni K Choueiri2, Axel Bex8.   

Abstract

INTRODUCTION: Designing adjuvant trials is challenging because of uncertainties of prevalence and outcome of high-risk renal cell cancer (RCC) despite use of validated risk scores. Our objective is to investigate how differences in eligibility criteria may impact on potential study results in RCC adjuvant trials. PATIENTS AND METHODS: RECUR is a multicenter European database capturing patient and tumor characteristics, recurrence patterns, and survival of those curatively treated for non-metastatic RCC from 2006 to 2011 without any adjuvant therapy. We used RECUR to evaluate prevalence, disease-free survival (DFS), and overall survival (OS) according to eligibility criteria of immunotherapy-based adjuvant trials IMMotion 010 (NCT03024996), Checkmate 914 (NCT03138512), Keynote-564 (NCT03142334), RAMPART (NCT03288532), and PROSPER (NCT03055013).
RESULTS: Of 3024 relevant patients in RECUR, 408 (13.5%), 725 (24%), 609 (20.1%), 1363 (45.1%), and 1071 (35.4%) met eligibility criteria for IMMotion-010, CheckMate-914, Keynote-564, RAMPART, and PROSPER, respectively. The median and 5-year DFS Kaplan-Meier estimates in RECUR corresponding to each trial eligibility criteria were: not reached and 69.6% for RAMPART; not reached and 64.5% for PROSPER; 109.3 months (95% confidence interval [CI], 83.9-134.6 months) and 57% for CheckMate-914; 75.8 months (95% CI, 52.7-98.8 months) and 54.3% for Keynote-564; and 43.6 months (95% CI, 30.8-56.4 months) and 45% for IMMotion-010. Our analysis may be limited by the retrospective design.
CONCLUSIONS: RECUR provides estimated DFS and OS benchmarks for placebo arms of adjuvant checkpoint inhibitor studies and hence likely time to trial reporting. Well-documented contemporary registries rather than past risk models should be used to design future adjuvant trials.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adjuvant studies; Adjuvant therapy; Clinical trials; Immunotherapy; Kidney cancer; Targeted therapy

Year:  2021        PMID: 33526329     DOI: 10.1016/j.clgc.2020.12.005

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  3 in total

1.  How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?

Authors:  Giuseppe Fallara; Alessandro Larcher; Giuseppe Rosiello; Daniele Raggi; Laura Marandino; Alberto Martini; Giuseppe Basile; Gianmarco Colandrea; Daniele Cignoli; Federico Belladelli; Chiara Re; Giacomo Musso; Francesco Cei; Roberto Bertini; Alberto Briganti; Andrea Salonia; Francesco Montorsi; Andrea Necchi; Umberto Capitanio
Journal:  World J Urol       Date:  2022-09-20       Impact factor: 3.661

2.  Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial.

Authors:  Robert J Motzer; Jean-François Martini; Keith A Ching; Alain Ravaud; Xinmeng J Mu; Michael Staehler; Daniel J George; Olga Valota; Xun Lin; Hardev S Pandha
Journal:  Nat Commun       Date:  2022-10-10       Impact factor: 17.694

3.  Identification of a Novel Renal Metastasis Associated CpG-Based DNA Methylation Signature (RMAMS).

Authors:  Jürgen Serth; Inga Peters; Olga Katzendorn; Tu N Dang; Joana Moog; Zarife Balli; Christel Reese; Jörg Hennenlotter; Alexander Grote; Marcel Lafos; Hossein Tezval; Markus A Kuczyk
Journal:  Int J Mol Sci       Date:  2022-09-23       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.